During a high-throughput screening the approved FDA diuretic ethacrynic acid (Table 1) was found to down-regulate Wnt/β-catenin signaling by inhibiting the formation of the β-catenin/Lef-1 complex [437, 438] in chronic lymphocytic leukemia (CLL) cells, although at a low IC50 (Table 1). Here, LEF1 is linked to B-cell chronic lymphocytic leukemia.